Core Viewpoint - Hims & Hers Health, Inc. faces significant challenges following the termination of its collaboration with Novo Nordisk and increasing scrutiny from U.S. lawmakers regarding safety concerns related to copycat weight loss drugs [1][2][5]. Company Developments - On July 25, 2025, Hims & Hers shares dropped significantly amid reports of lawmakers urging the FDA to take action against counterfeit weight loss drugs [1]. - Novo Nordisk ended its collaboration with Hims & Hers on June 23, 2025, citing concerns over deceptive marketing practices and illegal compounding of its FDA-approved drug Wegovy® [2][6]. - The collaboration, which began on April 29, 2025, was short-lived, lasting less than two months due to regulatory compliance issues raised by Novo Nordisk [6]. Legal Issues - Following Novo Nordisk's announcement, securities class action lawsuits were filed against Hims & Hers and its executives, representing investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025 [3][7]. - Legal claims allege that Hims & Hers misled investors regarding its regulatory compliance and the revenue potential from its GLP-1 drug offerings [7][8]. - The lawsuits assert that Hims & Hers engaged in deceptive promotion and sale of unauthorized versions of Wegovy®, exposing patients to risks and jeopardizing its relationship with Novo Nordisk [8][9]. Industry Context - Over 80 bipartisan lawmakers have expressed concerns about the rise of illegal and counterfeit anti-obesity medications, emphasizing the potential risks to patient safety [5]. - The scrutiny from lawmakers and the legal actions against Hims & Hers highlight the increasing regulatory pressures in the weight loss drug market, particularly concerning compliance and marketing practices [5][6].

RADNOR, Pa., Aug. 1, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, ...

Core Viewpoint - Novo Nordisk has significantly lowered its sales outlook for 2025 due to increased competition for its drugs Ozempic and Wegovy, leading to a substantial drop in its stock price [3]. Group 1: Company Performance - On July 29, 2025, Novo Nordisk reduced its sales forecast for 2025, attributing the change to heightened competition in the market for its key products [3]. - Following the announcement, Novo Nordisk's American Depositary Receipt (ADR) price decreased by $15.06, or 21.83%, closing at $53.94 per ADR on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud or unlawful business practices by Novo Nordisk and its officers or directors [1].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - A second complaint with similar claims has also been filed against Hims & Hers [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform, which contains the active ingredient semaglutide [3]. Group 3: Allegations and Stock Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could sell both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. [Click here for information about joining the class action] CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 On July 29, 2025, Novo Nordisk significantly lowered its sales outlook for 2025, citing the impact of ...

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Hims & Hers Health, Inc. investors who were adversely affected by alleged securities fraud between April 29, 2025 and June 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.co ...

U.S.-listed shares of Novo Nordisk fell sharply for a second straight day Wednesday, this time after Bank of America downgraded the stock to "neutral" from "buy." https://t.co/i7jKloW8eP ...

Ozempic maker Novo Nordisk A/S ( NVO ), was down by no less than 22% in yesterday's trading session. A series of key developments occurred recently, including the E.U.-U.S. trade deal, the appointment of a new CEO, and a brief financial update for Q2 2025. But the key Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflec ...

Novo Nordisk​’s ​new CEO, Maziar Mike Doustdar, will ​contend with a challenging landscape in the U.S., where ​the company faces its biggest competitive threats https://t.co/0cqKRW8yeb ...

Core Insights - Novo Nordisk's shares fell 21.8% after the company revised its 2025 sales and operating profit growth outlook downward, impacting earnings per share [1][9] - The new sales growth forecast is 8-14%, down from 13-21%, and operating profit growth is now projected at 10-16%, reduced from 16-24% [1][9] Sales and Market Dynamics - The guidance cut is attributed to weaker-than-expected momentum in key markets for semaglutide-based drugs, Wegovy and Ozempic, particularly in the U.S. obesity market [2][3] - Ongoing challenges include competition from unsafe compounded GLP-1 drugs and illegal sales of counterfeit semaglutide products, which are affecting Wegovy's market uptake [2] - Despite some growth from NovoCare Pharmacy and telehealth partnerships, overall uptake remains limited, and Ozempic faces increasing competition in the U.S. diabetes market [3] Financial Performance - Preliminary earnings per American Depositary Receipt were reported at 91 cents, missing the Zacks Consensus Estimate of 94 cents, while sales increased by 18% at constant exchange rates [4][9] - Operating profit rose by 40% at constant exchange rates in Q2 2025, primarily due to an impairment charge recognized in the previous year [4] Competitive Landscape - Eli Lilly is a significant competitor in the obesity space, with its drugs Mounjaro and Zepbound generating combined sales of $6.15 billion in Q1 2025, accounting for approximately 48% of Lilly's total revenues [5] - Other companies, such as Viking Therapeutics, are also advancing in the development of GLP-1-based candidates, with ongoing late-stage studies for their investigational obesity drug VK2735 [6] Stock Performance and Valuation - Year-to-date, Novo Nordisk shares have declined by 37.3%, underperforming the industry and the S&P 500, which saw a growth of 0.9% [7][8] - The company's shares are trading at a price/earnings ratio of 12.49, lower than the industry average of 15.11 and significantly below its five-year mean of 29.25 [11] Earnings Estimates - Earnings estimates for 2025 have improved from $3.84 to $3.98 per share over the past 60 days, while 2026 estimates have decreased from $4.64 to $4.56 [15] - The stock's return on equity over the trailing 12 months is 80.95%, outperforming the large drugmaker industry average of 33.55% [19]